Navigation Links
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive data from a Phase II clinical study of Rituxan(R) (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells.

"There remains a great need for safe and effective treatments for patients with RRMS," said Stephen Hauser, MD, Professor and Chair, Department of Neurology, University of California, San Francisco. "These Phase II results are very encouraging and suggest B-cells play a key role in MS. They also lend support to the concept that selective targeting of B-cells may be an important approach to treating this debilitating disease."

In this Phase II double-blind, placebo-controlled study that evaluated the safety and efficacy of Rituxan in adult patients with RRMS, 104 patients were randomized to receive either a single treatment course of Rituxan (two infusions separated by two weeks) or placebo. The primary endpoint was defined as the total number of gadolinium-enhancing T1 lesions at weeks 12, 16, 20 and 24, as measured by serial MRI scans of the brain. The total number of gadolinium lesions at weeks 12, 16, 20 and 24 was statistically significantly reduced in patients receiving Rituxan compared to those receiving placebo (p less than 0.0001). At week 24, the total cumulative mean number of gadolinium lesions per patient was reduced by 91 percent, to 0.5 in the Rituxan-treated group from 5.5 in the placebo group.

In addition, the proportion of patients with relapses over 24 weeks in the Rituxan-treated arm was 14.5 percent compared to 34.3 percent in the placebo arm (58 percent relative reduction) (p = 0.0238).

With the exception of infusion associated adverse events,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/27/2014)... , Aug. 27, 2014 /CNW/ - Covalon Technologies Ltd. (the ... announces the following financial results for its third quarter of ... 30, 2014: , Revenue of $1,291,378, a 13% ... , Net loss for the quarter of $240,156 compared to ... prior year For the nine months ended ...
(Date:8/27/2014)... 27, 2014  After the February 2014 launch of ... solution for medical practices and management companies, Prime ... new software. "The feedback has been great," ... "The sheer number of demos and new sign-ups is ... for these types of software features." ...
(Date:8/27/2014)... , Aug. 27, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , today announced the results of the Company,s ... 2014 in Beijing , PRC. The required quorum, ... The Company,s shareholders approved the following proposals:  ... Lam Lo , Simon Anderson , Kenneth Lee ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... derivative compound series,show highly selective PI3K-inhibition which ... 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris,Inc. , ... on,endocrine therapy and oncology, today presented an ... pyridopyrazine derivatives,with high selectivity for PI3K inhibition, ...
... With Improved Potential to,Battle Their Disease, PASADENA, ... Inc., a majority-owned subsidiary of Arrowhead,Research Corporation ... will be featured in a poster presentation ... (AACR) Annual,Meeting. In particular, this poster includes ...
Cached Medicine Technology:AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4
(Date:8/27/2014)... PA (PRWEB) August 27, 2014 What’s ... of this year’s 87th Annual Scripps National Spelling Bee? ... for a tour of internationally renowned Wills Eye Hospital.     ... like to be an ophthalmologist one day. , Wills ... eye surgery and the latest hi-tech visual diagnostic testing. ...
(Date:8/27/2014)... NC. SonaCare Medical, LLC, the global leader in ... 15 HIFU devices over the past twelve months pointing ... company’s ablation technology. , “It is truly exciting ... the past year, especially since we are now heading ... active sales period,” says Mike Klein, CEO of SonaCare ...
(Date:8/27/2014)... -- A new study finds that continuous positive airway ... sleep apnea. CPAP is widely used to treat ... which the airway relaxes and narrows during sleep, causing ... daytime drowsiness. CPAP keeps the airway open ... nose via a mask that is worn during sleep. ...
(Date:8/27/2014)... (HealthDay News) -- Overconfident people are better at convincing ... and therefore are more likely to get promotions and ... researchers added that these "self-deceived" people are also more ... greater risks. And finally, people who underestimate themselves ... to the British researchers. Their findings were published Aug. ...
(Date:8/27/2014)... each receive $100,000 in funding to launch pilot programs ... for patients served by community health centers. The program ... and is part of the group,s effort to reach ... over receiving regular screening for colorectal cancer by 2018. ... are: Port Royal, South Carolina; New Haven, Connecticut; and ...
Breaking Medicine News(10 mins):Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2Health News:SonaCare Medical Announces Twelve Months Sales Results of Fifteen HIFU Devices 2Health News:Sleep Apnea Treatment Helps Seniors, Study Finds 2Health News:Overconfident Folks May Blind Others to Their Real Abilities 2Health News:Pilot program aims to improve cancer screening, specialty care in community health centers 2Health News:Pilot program aims to improve cancer screening, specialty care in community health centers 3
... the tourist resort city of Livingstone were tested for bird ... backyards'. // ,Simon Miti, the permanent secretary at ... thorough investigation of the outbreak'. ,The number of ... residents who cooked and ate the dead chickens have been ...
... is found to enhance educational achievements and combat other behavioral ... that it has a positive effect on the kids suffering ... responded better to Omega 3 fish oils than to the ... found that fish oil is very essential for the kids. ...
... the killer of Lin and Megan Russell has petitioned the High ... public since it would be misused by the press. ... committed a decade ago. Stone's lawyer, Richard Clayton QC said that ... be seriously misused by the tabloid press. ,Mr Clayton ...
... Delhi Police summoned three doctors of the Indraprastha Apollo ... //on the condition of Rahul Mahajan, who was admitted ... overdose. ,"We have summoned the doctors and ... of police, heading the probe against the hospital. ...
... introduce a common school system in the country, educationists ... the primary education //system and remove disparities among students. ... school system in the country so that all students ... students," said Madhu Prasad, educationist and a professor in ...
... According to a new study published in the Journal ... epileptic seizures by inducing rhythmical //electrical activity in the ... the hippocampus. The researchers found that, by imposing a ... reduce epileptic seizures by 86-97%. ,The study ...
Cached Medicine News:Health News:Police Summoned Apollo Doctors in Rahul Mahajan’s Cas 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 3
... assembly. Superb Bi-Polar range of ... Superior pull-out and lever-out strength. ... 44, 48, 52, 56, 60 ... component for all shells. Increased ...
... index. A/P and lateral fins with holes ... medial hole, humeral / glenoid diametral curvature ... textured proximal surface to provide enhanced proximal ... cement, six stem sizes, fifteen head sizes ...
...
...
Medicine Products: